Imported loiasis in France: a retrospective analysis of 167 cases with comparison between sub-Saharan and non sub-Saharan African patients

Table 4 Treatment outcomes in 149 patients with imported loiasis

	ivermectin^ab		diethylcarbamazine^cd		ivermectin^a then diethylcarbamazine^c
	N = 113 (75.8%)		N = 10 (6.7%)		N = 26 (17.4%)
	N	%	N	%	N	%
Outcomes:
failure	10	8.8	2	20	2	7.6
full cure	59	52.2	0	0	20	76.9
partial cure	0	0	5	50	2	7.6
loss of follow up	44	38.9	3	30	2	7.6
preventive treatment of post-treatment reaction	15	13.2	4	40	7	26.9
post-treatment reaction	5	4.4	2	20	4	15.3

^abetween 1and 6 courses (1 course: 62.8%; 2: 17.8%; 3: 7.7%; 4: 6.2%; 5: 2.3%; 6: 3.1%), 10 (7.1%) patients received only 1 course, associated with albendazole in 4 cases
^b200 μg/kg per course
^cprogressive dosage (initial dosage between 10 and 75 mg, final dosage 200–400 mg for 21 days)
^dTwo patients with a high microfilaremia (38,200 and 50,000/mL, respectively) were treated with filariopheresis followed by diethylcarbamazine without significant adverse event

ISSN: 1471-2334